Premium
Syndecan‐4 Enhances Therapeutic Angiogenesis after Hind Limb Ischemia in Mice with Type 2 Diabetes
Author(s) -
Das Subhamoy,
Monteforte Anthony J.,
Singh Gunjan,
Majid Marjan,
Sherman Michael B.,
Dunn Andrew K.,
Baker Aaron B.
Publication year - 2016
Publication title -
advanced healthcare materials
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.288
H-Index - 90
eISSN - 2192-2659
pISSN - 2192-2640
DOI - 10.1002/adhm.201500993
Subject(s) - syndecan 1 , angiogenesis , hindlimb , ischemia , perfusion , medicine , cancer research , limb ischemia , endocrinology , biology , cell , genetics
Delivering syndecan‐4 with FGF‐2 improves the effectiveness of FGF‐2 therapy for ischemia in the diabetic disease state. The syndecan‐4 proteoliposomes significantly enhance in vitro tubule formation as well as blood perfusion and vessel density in the ischemic hind limbs of diseased ob/ob mice. Syndecan‐4 therapy also induces a marked immunomodulation in the tissues, increasing the polarization of macrophages toward the M2 phenotype.